Gene Editing Breakthrough: Hope for Rare Diseases, But Challenges Loom
For the first time, a commercial authorization request is being prepared for a therapy tested on just two individuals – a Canadian teenager and a 57-year-old American programmer. Both were born with Chronic Granulomatous Disease (CGD), a severe immunodeficiency where even a common cold can be life-threatening. This marks a potential turning point in how the FDA approaches treatments for ultra-rare conditions.
A New Era of Personalized Medicine
The treatment, known as PM359 and developed by Prime Medicine, utilizes an advanced form of CRISPR editing. Unlike traditional CRISPR which cuts DNA, this “prime editing” approach can rewrite short DNA sequences, correcting a specific deletion in the NCF1 gene responsible for CGD. The process involves extracting a patient’s stem cells, correcting the genetic defect ex vivo (outside the body), and then reintroducing them after chemotherapy prepares the body.
David Liu, the inventor of prime editing, describes the Canadian teenager, who was the first to receive the treatment, as now being “in health, stable, and with a functioning immune system.” The National Institutes of Health have similarly confirmed the positive health status of the second patient.
Living with CGD: A Glimpse into Patient Lives
CGD significantly restricts daily life. Tracy Atteberry, the American patient, described a life filled with limitations: avoiding gardening, caves, even Christmas trees, and needing to wear a mask in public. He now looks forward to simple pleasures, like owning a houseplant, without constant fear of infection.
The FDA’s Shifting Stance on Rare Disease Therapies
Traditionally, clinical trials require larger patient groups and longer follow-up periods. However, the FDA is signaling a willingness to be more flexible for rare diseases, inspired in part by the case of “Baby KJ,” another pioneering gene editing patient. In February 2026, the FDA published a 22-page guide outlining considerations for approving individualized therapies based on a “plausible mechanism” of action.
This shift comes with debate. Experts acknowledge the necessitate for speed in bringing treatments to those with limited options, but also emphasize the importance of maintaining safety standards. Finding the right balance will be crucial.
Financial Hurdles and the Future of Access
Despite the scientific progress, significant challenges remain. Ex vivo gene editing is expensive and requires specialized facilities. The cost of PM359 was initially projected at $20-30 million per patient, but Prime Medicine’s funding has turn into strained, potentially halting the trial. Currently, only around 50 people in the US are considered eligible for this therapy, representing just a quarter of those affected by CGD.
The sustainability of advanced therapies for rare and ultra-rare diseases remains a major concern. Until in vivo (direct-in-body) gene editing becomes feasible, widespread access will be limited.
Will Two Patients Be Enough?
The question now is whether the FDA will approve PM359 based on data from just two patients observed for a relatively short period. This decision could set a precedent for future approvals of therapies for ultra-rare conditions, potentially accelerating access to life-changing treatments.
Did you know?
Chronic Granulomatous Disease was once considered a fatal childhood illness, with most children not surviving past the age of ten.
FAQ
Q: What is prime editing?
A: Prime editing is an advanced form of CRISPR gene editing that can rewrite short DNA sequences without cutting the DNA strand.
Q: What is Chronic Granulomatous Disease (CGD)?
A: CGD is a rare genetic disorder that weakens the immune system, making individuals highly susceptible to infections.
Q: Is this therapy widely available?
A: Currently, the therapy is still in the experimental phase and access is extremely limited due to cost and logistical challenges.
Q: What is the FDA’s role in all of this?
A: The FDA is considering whether to approve the therapy based on data from a small number of patients, potentially paving the way for a more flexible approval process for rare disease treatments.
Pro Tip: Stay informed about advancements in gene therapy by following reputable sources like the Osservatorio Terapie Avanzate (https://www.osservatorioterapieavanzate.it/) and the FDA (https://www.fda.gov/).
Want to learn more about gene editing and its potential? Explore our comprehensive guide to genomic editing.
Related reading